Literature DB >> 20307208

Control of immunity by the TNFR-related molecule OX40 (CD134).

Michael Croft1.   

Abstract

TNFR/TNF superfamily members can control diverse aspects of immune function. Research over the past 10 years has shown that one of the most important and prominent interactions in this family is that between OX40 (CD134) and its partner OX40L (CD252). These molecules strongly regulate conventional CD4 and CD8 T cells, and more recent data are highlighting their ability to modulate NKT cell and NK cell function as well as to mediate cross-talk with professional antigen-presenting cells and diverse cell types such as mast cells, smooth muscle cells, and endothelial cells. Additionally, OX40-OX40L interactions alter the differentiation and activity of regulatory T cells. Blocking OX40L has produced strong therapeutic effects in multiple animal models of autoimmune and inflammatory disease, and, in line with a prospective clinical future, reagents that stimulate OX40 signaling are showing promise as adjuvants for vaccination as well as for treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307208      PMCID: PMC2882161          DOI: 10.1146/annurev-immunol-030409-101243

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  134 in total

1.  Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).

Authors:  S D Pippig; C Peña-Rossi; J Long; W R Godfrey; D J Fowell; S L Reiner; M L Birkeland; R M Locksley; A N Barclay; N Killeen
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

Authors:  J R Maxwell; A Weinberg; R A Prell; A T Vella
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

3.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

Authors:  I Gramaglia; A D Weinberg; M Lemon; M Croft
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation.

Authors:  S Kawamata; T Hori; A Imura; A Takaori-Kondo; T Uchiyama
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

5.  OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors.

Authors:  Y Ohshima; L P Yang; T Uchiyama; Y Tanaka; P Baum; M Sergerie; P Hermann; G Delespesse
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

6.  OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells.

Authors:  Seyed Fazlollah Mousavi; Pejman Soroosh; Takeshi Takahashi; Yasunobu Yoshikai; Hao Shen; Leo Lefrançois; Jannie Borst; Kazuo Sugamura; Naoto Ishii
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

7.  OX40 drives protective vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Magdalini Moutaftsi; Shane Crotty; Alessandro Sette; Michael Croft
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.

Authors:  Keli L Hippen; Paul Harker-Murray; Stephen B Porter; Sarah C Merkel; Aryel Londer; Dawn K Taylor; Megan Bina; Angela Panoskaltsis-Mortari; Pablo Rubinstein; Nico Van Rooijen; Tatiana N Golovina; Megan M Suhoski; Jeffrey S Miller; John E Wagner; Carl H June; James L Riley; Bruce R Blazar
Journal:  Blood       Date:  2008-07-21       Impact factor: 22.113

9.  The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells.

Authors:  Johanna Kober; Judith Leitner; Christoph Klauser; Ramona Woitek; Otto Majdic; Johannes Stöckl; Dietmar Herndler-Brandstetter; Beatrix Grubeck-Loebenstein; Birgit M Reipert; Winfried F Pickl; Katharina Pfistershammer; Peter Steinberger
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

10.  CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1.

Authors:  S Flynn; K M Toellner; C Raykundalia; M Goodall; P Lane
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  212 in total

Review 1.  TNF superfamily in inflammatory disease: translating basic insights.

Authors:  Michael Croft; Wei Duan; Heonsik Choi; So-Young Eun; Shravan Madireddi; Amit Mehta
Journal:  Trends Immunol       Date:  2011-12-13       Impact factor: 16.687

2.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

3.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

Review 4.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 5.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

6.  Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand.

Authors:  Junyan Han; Azzeddine Dakhama; Yi Jia; Meiqin Wang; Wanjiang Zeng; Katsuyuki Takeda; Yoshiki Shiraishi; Masakazu Okamoto; Steven F Ziegler; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

7.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

8.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

9.  TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.

Authors:  Peixiang Lan; Yihui Fan; Yue Zhao; Xiaohua Lou; Howard P Monsour; Xiaolong Zhang; Yongwon Choi; Yaling Dou; Naoto Ishii; Rafik M Ghobrial; Xiang Xiao; Xian Chang Li
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

10.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.